Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism
Identifieur interne : 000E68 ( Main/Corpus ); précédent : 000E67; suivant : 000E69Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism
Auteurs : E. Schneider ; H. Baas ; P.-A. Fischer ; G. JappSource :
- Journal of Neurology [ 0340-5354 ] ; 1985-03-01.
Abstract
Summary: In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.
Url:
DOI: 10.1007/BF00314036
Links to Exploration step
ISTEX:76A9FFC571B7544226B519177C7B5C23DA0B320CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title><author><name sortKey="Schneider, E" sort="Schneider, E" uniqKey="Schneider E" first="E." last="Schneider">E. Schneider</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Baas, H" sort="Baas, H" uniqKey="Baas H" first="H." last="Baas">H. Baas</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Fischer, P A" sort="Fischer, P A" uniqKey="Fischer P" first="P.-A." last="Fischer">P.-A. Fischer</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Japp, G" sort="Japp, G" uniqKey="Japp G" first="G." last="Japp">G. Japp</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:76A9FFC571B7544226B519177C7B5C23DA0B320C</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1007/BF00314036</idno><idno type="url">https://api.istex.fr/document/76A9FFC571B7544226B519177C7B5C23DA0B320C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title><author><name sortKey="Schneider, E" sort="Schneider, E" uniqKey="Schneider E" first="E." last="Schneider">E. Schneider</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Baas, H" sort="Baas, H" uniqKey="Baas H" first="H." last="Baas">H. Baas</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Fischer, P A" sort="Fischer, P A" uniqKey="Fischer P" first="P.-A." last="Fischer">P.-A. Fischer</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author><author><name sortKey="Japp, G" sort="Japp, G" uniqKey="Japp G" first="G." last="Japp">G. Japp</name><affiliation><mods:affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="ISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1985-03-01">1985-03-01</date><biblScope unit="volume">232</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="24">24</biblScope><biblScope unit="page" to="28">28</biblScope></imprint><idno type="ISSN">0340-5354</idno></series><idno type="istex">76A9FFC571B7544226B519177C7B5C23DA0B320C</idno><idno type="DOI">10.1007/BF00314036</idno><idno type="ArticleID">Art5</idno><idno type="ArticleID">BF00314036</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-5354</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>E. Schneider</name><affiliations><json:string>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</json:string></affiliations></json:item><json:item><name>H. Baas</name><affiliations><json:string>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</json:string></affiliations></json:item><json:item><name>P.-A. Fischer</name><affiliations><json:string>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</json:string></affiliations></json:item><json:item><name>G. Japp</name><affiliations><json:string>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</json:string></affiliations></json:item></author><articleId><json:string>Art5</json:string><json:string>BF00314036</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.</abstract><qualityIndicators><score>6.036</score><pdfVersion>1.3</pdfVersion><pdfPageSize>598 x 792 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1614</abstractCharCount><pdfWordCount>3120</pdfWordCount><pdfCharCount>19787</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>243</abstractWordCount></qualityIndicators><title>Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title><genre><json:string>research-article</json:string></genre><host><volume>232</volume><pages><last>28</last><first>24</first></pages><issn><json:string>0340-5354</json:string></issn><issue>1</issue><subject><json:item><value>Neurosciences</value></json:item><json:item><value>Neuroradiology</value></json:item><json:item><value>Neurology</value></json:item></subject><journalId><json:string>415</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1432-1459</json:string></eissn><title>Journal of Neurology</title><publicationDate>1985</publicationDate><copyrightDate>1985</copyrightDate></host><publicationDate>1985</publicationDate><copyrightDate>1985</copyrightDate><doi><json:string>10.1007/BF00314036</json:string></doi><id>76A9FFC571B7544226B519177C7B5C23DA0B320C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/76A9FFC571B7544226B519177C7B5C23DA0B320C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/76A9FFC571B7544226B519177C7B5C23DA0B320C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/76A9FFC571B7544226B519177C7B5C23DA0B320C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><p>SPRINGER</p></availability><date>1984-10-16</date></publicationStmt><notesStmt><note>Original Investigations</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title><author corresp="yes"><persName><forename type="first">E.</forename><surname>Schneider</surname></persName><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation></author><author><persName><forename type="first">H.</forename><surname>Baas</surname></persName><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation></author><author><persName><forename type="first">P.-A.</forename><surname>Fischer</surname></persName><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation></author><author><persName><forename type="first">G.</forename><surname>Japp</surname></persName><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation></author></analytic><monogr><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="JournalID">415</idno><idno type="pISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><idno type="IssueArticleCount">15</idno><idno type="VolumeIssueCount">6</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1985-03-01"></date><biblScope unit="volume">232</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="24">24</biblScope><biblScope unit="page" to="28">28</biblScope></imprint></monogr><idno type="istex">76A9FFC571B7544226B519177C7B5C23DA0B320C</idno><idno type="DOI">10.1007/BF00314036</idno><idno type="ArticleID">Art5</idno><idno type="ArticleID">BF00314036</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1984-10-16</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Neurosciences</term></item><item><term>Neuroradiology</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1984-10-16">Created</change><change when="1985-03-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/76A9FFC571B7544226B519177C7B5C23DA0B320C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>415</JournalID><JournalPrintISSN>0340-5354</JournalPrintISSN><JournalElectronicISSN>1432-1459</JournalElectronicISSN><JournalTitle>Journal of Neurology</JournalTitle><JournalAbbreviatedTitle>J Neurol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Neurosciences</JournalSubject><JournalSubject Type="Secondary">Neuroradiology</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>232</VolumeIDStart><VolumeIDEnd>232</VolumeIDEnd><VolumeIssueCount>6</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>1</IssueIDStart><IssueIDEnd>1</IssueIDEnd><IssueArticleCount>15</IssueArticleCount><IssueHistory><CoverDate><Year>1985</Year><Month>3</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag Berlin Heidelberg</CopyrightHolderName><CopyrightYear>1985</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art5"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00314036</ArticleID><ArticleDOI>10.1007/BF00314036</ArticleDOI><ArticleSequenceNumber>5</ArticleSequenceNumber><ArticleTitle Language="En">Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</ArticleTitle><ArticleCategory>Original Investigations</ArticleCategory><ArticleFirstPage>24</ArticleFirstPage><ArticleLastPage>28</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>8</Month><Day>25</Day></RegistrationDate><Received><Year>1984</Year><Month>10</Month><Day>16</Day></Received><Accepted><Year>1985</Year><Month>1</Month><Day>4</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1985</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>415</JournalID><VolumeIDStart>232</VolumeIDStart><VolumeIDEnd>232</VolumeIDEnd><IssueIDStart>1</IssueIDStart><IssueIDEnd>1</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>E.</GivenName><FamilyName>Schneider</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><FamilyName>Baas</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>P.-A.</GivenName><FamilyName>Fischer</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>G.</GivenName><FamilyName>Japp</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Abteilung für Neurologie</OrgDivision><OrgName>Klinikum der Universität</OrgName><OrgAddress><Street>Schleusenweg 2-16</Street><Postcode>6000</Postcode><City>Frankfurt 71</City><Country>Federal Republic of Germany</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.</Para></Abstract><KeywordGroup Language="En"><Heading>Key words</Heading><Keyword>Parkinsonism</Keyword><Keyword>Mesulergine</Keyword><Keyword>Dopamine agonist</Keyword><Keyword>Long-term effects</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">E.</namePart><namePart type="family">Schneider</namePart><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Baas</namePart><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.-A.</namePart><namePart type="family">Fischer</namePart><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Japp</namePart><affiliation>Abteilung für Neurologie, Klinikum der Universität, Schleusenweg 2-16, 6000, Frankfurt 71, Federal Republic of Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">1984-10-16</dateCreated><dateIssued encoding="w3cdtf">1985-03-01</dateIssued><copyrightDate encoding="w3cdtf">1985</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.</abstract><note>Original Investigations</note><relatedItem type="host"><titleInfo><title>Journal of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1985-03-01</dateIssued><copyrightDate encoding="w3cdtf">1985</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Neurosciences</topic><topic>Neuroradiology</topic><topic>Neurology</topic></subject><identifier type="ISSN">0340-5354</identifier><identifier type="eISSN">1432-1459</identifier><identifier type="JournalID">415</identifier><identifier type="IssueArticleCount">15</identifier><identifier type="VolumeIssueCount">6</identifier><part><date>1985</date><detail type="volume"><number>232</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="pages"><start>24</start><end>28</end></extent></part><recordInfo><recordOrigin>Springer-Verlag Berlin Heidelberg, 1985</recordOrigin></recordInfo></relatedItem><identifier type="istex">76A9FFC571B7544226B519177C7B5C23DA0B320C</identifier><identifier type="DOI">10.1007/BF00314036</identifier><identifier type="ArticleID">Art5</identifier><identifier type="ArticleID">BF00314036</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1985</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:76A9FFC571B7544226B519177C7B5C23DA0B320C
|texte= Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |